Innovation that Drives Excellence

Over the years, innovation at Disto has been the result of our response to our clients’ drug developmental needs. One of the earliest products developed by us was Pellets of Phenylpropanolamine Hydrochloride + Chlorpheniramine Maleate SR. This was taken up and developed before Phenylpropanolamine was banned.

Soon after, we developed Orlistat pellets using a solvent-based formulation. Back then, there was no USP specification for this drug. Later on, with the USP specifications for Orlistat in place, we started facing issues with the impurities which pushed us to develop and validate an aqueous method for this formulation. With this method in place, there is no degradation during the process, stability is better and the product is more in line with specifications, with dissolution similar to innovator product, Xenical™.

Another important product for us is Tamsulosin that has been registered in Russia and for which BE studies have successfully completed by our client in Russia. With this product and with others, our aim has always been to make a product which will be bioequivalent ready. This is something we ensure by undertaking a thorough understanding of the innovator product, its properties and extensive dissolution testing.

Our association with all of our clients across the globe has been along similar lines wherein we have treated our clients’ challenges as our own and found ways to successfully overcome them.